What Is ‘Metabolic Health,’ and Why Does It Matter?
January 16, 2026 / metabolic health definition / obesity insulin resistance / cardiovascular disease risk / GLP-1 obesity treatment / metabolic syndrome prevention
Metabolic health refers to the absence of metabolic syndrome components like obesity, hypertension, and insulin resistance. Poor metabolic health increases the risk of cardiovascular disease, diabetes, and cancer, but early intervention via lifestyle changes or GLP-1 therapy can help.
Detailed Liver Atlas Links Macrophage Activity to MASH Progression
January 16, 2025 / MASH disease progression / lipid-associated macrophages / liver multi-omics atlas / MASLD immune pathways / metabolic liver inflammation
A spatial multi-omics liver atlas identified lipid-associated macrophages and MITF-driven immune–metabolic programs as key regulators of MASH progression, highlighting localized macrophage–lipid interactions as potential therapeutic targets.
Unraveling lipedema: comprehensive insights and the path to future discoveries
January 17, 2026 / lipedema diagnosis imaging / estrogen adipose accumulation / lipedema genetic factors / chronic fat disorder / liposuction treatment lipedema
Lipedema is a chronic, estrogen-influenced disorder marked by symmetrical lower-body fat accumulation. This review highlights its polygenic basis, histological features, diagnostic imaging limitations, and symptom-focused therapies, emphasizing the urgent need for improved diagnostic tools and targeted treatments.
Screen time may increase body fat in children
January 15, 2026 / childhood obesity screen time / visceral fat accumulation children / cardiorespiratory fitness metabolic health / screen time physical inactivity / pediatric adiposity metabolic markers
Excessive screen time in children is linked to increased visceral fat and poorer metabolic health, while higher cardiorespiratory fitness significantly mitigates these effects. Reducing screen time and promoting physical activity may improve adiposity-related outcomes in school-aged children.
Interax and Alveus Therapeutics partner in metabolic disease
January 16, 2026 / metabolic disease drug development / obesity small molecule therapy / durable weight loss treatment / obesity drug tolerability / Interax Alveus partnership
Interax Biotech and Alveus Therapeutics formed a research and licensing partnership to develop a novel small‑molecule therapy for metabolic disease, aiming to achieve durable weight loss with improved tolerability compared with current obesity treatments.
Night-time changes in metabolism may be driving common liver disease
January 13, 2026 / MASLD / liver fat metabolism / insulin resistance night / circadian liver disease / Oxford liver study
Oxford researchers found that metabolic dysfunction-associated steatotic liver disease (MASLD) worsens overnight due to increased liver fat production and insulin resistance, highlighting circadian metabolic disruption as a key driver—even after weight loss reduces liver fat.
The Obesity Association Publishes New Standards of Care Section on Obesity Medications
January 13, 2026 / obesity medications guidelines / pharmacologic obesity treatment / ADA obesity care / MASH diabetes hypertension / long-term obesity management
The Obesity Association released new pharmacologic treatment guidelines emphasizing personalized, long-term obesity care. Recommendations cover drug selection for comorbidities like diabetes and MASH, discourage compounded products, and stress nutritional monitoring and clinical infrastructure support.
Eating less ultraprocessed food supports healthier aging, nutrition research shows
January 14, 2026 / ultraprocessed / aging / metabolism / nutrition / diet
Reducing ultraprocessed food intake to under 15% of daily calories significantly improved metabolic and appetite regulation markers in older adults, regardless of diet type, without requiring calorie restriction or lifestyle changes, according to a new Clinical Nutrition study.
Light daily movement linked to longer life in cardiometabolic disease
January 14, 2026 / cardiometabolic / light activity / mortality / CKM syndrome / physical activity
Light daily physical activity was associated with a 14–20% reduction in all-cause mortality among adults with cardiovascular-kidney-metabolic syndrome, including advanced stages, suggesting feasible movement-based interventions can improve survival when moderate-to-vigorous exercise is not attainable.
Metabolic Bariatric Surgery Tied to Improvement in Psoriasis Outcomes
January 14, 2026 / bariatric / psoriasis / weight loss / Roux-en-Y / dermatology
Metabolic bariatric surgery significantly improves psoriasis outcomes, including reduced severity, treatment need, and skin involvement. Roux-en-Y gastric bypass showed the most benefit, with 69.5% of patients experiencing improvement or remission, supporting further large-scale clinical studies.
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
January 16, 2026 / LXR / MASLD / hypertriglyceridemia / lipid-lowering / TLC-2716
OrsoBio’s TLC-2716, a liver-targeted LXR inverse agonist, demonstrated strong lipid-lowering effects and safety in Phase 1 trials. The drug shows promise for treating severe hypertriglyceridemia and MASLD, with Phase 2a data expected in 2026.
Immunis Announces Preliminary Results from First-Ever Phase 2 Study of a Secretome-Based Biologic Showing Weight Loss with Preserved Muscle and Improved Gait Speed in Obese Sarcopenic Seniors
January 14, 2026 / secretome / sarcopenia / weight-loss / gait-speed / regenerative-therapy
Immunis’ Phase 2 trial of IMM01-STEM, a secretome-based biologic, shows improved gait speed, weight loss, and preserved muscle in obese seniors with sarcopenia, indicating potential for enhancing mobility and metabolic health in aging populations.
Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation
January 15, 2026 / Eli-Lilly / NLRP3-inhibitor / metabolic-health / obesity-inflammation / Ventyx-acquisition
Eli Lilly’s $1.2B acquisition of Ventyx Biosciences adds NLRP3 inhibitor VTX3232 to its metabolic portfolio, enabling combined treatment of obesity and chronic inflammation—advancing a new standard for cardiometabolic care beyond weight loss alone.
GLP‑1s for MASLD and MASH: Turning Metabolic Therapy Toward the Liver
January 16, 2026 / GLP-1 / MASLD / MASH / liver-health / metabolic-therapy
GLP-1 receptor agonists show promise beyond diabetes and obesity, offering liver-specific benefits for patients with MASLD and MASH by improving metabolic function and reducing hepatic fat, reshaping treatment strategies for liver-related metabolic diseases.
New drug candidate reverses metabolic liver disease and fibrosis, pre-clinical data show
January 13, 2025 / MASH / liver-fibrosis / metabolic-disease / drug-candidate / preclinical-data
A novel drug candidate from Espervita Therapeutics shows preclinical success in reversing liver fibrosis linked to MASH, offering a promising treatment pathway for metabolic liver disease where current therapies are limited or ineffective.
Semaglutide May Improve Liver Outcomes, Regardless of Weight Loss Effects in MASH: Daily Dose
January 15, 2026 / semaglutide / MASH / liver-outcomes / fibrosis-reduction / ALT-improvement
Semaglutide 2.4 mg improved liver biomarkers and histological outcomes in MASH patients, even among those with minimal weight loss, suggesting liver-specific benefits independent of semaglutide’s weight-reducing effects.
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After New Pfizer Partnership In Metabolic Liver Disease
January 15, 2026 / MASH-treatment / DGAT2-inhibitor / liver-fat-reduction / Pfizer-partnership / metabolic-disease
Madrigal Pharmaceuticals partnered with Pfizer to advance ervogastat, a DGAT-2 inhibitor targeting liver fat and inflammation in MASH. The deal supports future combination therapies in metabolic liver disease and strengthens Madrigal’s long-term growth prospects.
Liver Fat Reduction Varied Across Pharmacologic Treatments for MASH
January 15, 2026 / MASH-treatment / liver-fat / MRI-PDFF / fibrosis-regression / pharmacologic-therapy
A network meta-analysis of 41 drugs for MASH found aldafermin, pegozafermin, and pioglitazone most effective at reducing liver fat via MRI-PDFF, though fat reduction did not always align with fibrosis improvement or long-term outcomes.
NRF1 is upregulated by docosahexaenoic acid to ameliorate MASH through the inhibition of ER stress
January 16, 2025 / MASH-treatment / DHA-NRF1 / ER-stress / liver-inflammation / metabolic-liver-disease
Docosahexaenoic acid (DHA) upregulates NRF1, reducing ER stress and oxidative damage to improve MASH outcomes in mice. NRF1 enhances proteasome function, making it a promising therapeutic target for managing metabolic liver disease.